A PRKAG2 mutation causes biphasic changes in myocardial AMPK activity and does not protect against ischemia

Biochemical and Biophysical Research Communications

Volumn 360, Issue 2, 2007, Pages 381-387

  Banerjee, Sanjay K ^a   Ramani, Ravi ^a   Saba, Samir ^a   Rager, Jennifer ^a   Tian, Rong ^b   Mathier, Michael A ^a   Ahmad, Ferhaan ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

AMPK; Cardiac hypertrophy; Glycogen cardiomyopathy; Myocardial ischemia reperfusion; Transgenic mouse model

Indexed keywords

ASPARTIC ACID; GLYCOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN DERIVATIVE; PROTEIN KINASE, AMP ACTIVATED, GAMMA 2 NON CATALYTIC SUBUNIT PROTEIN; THREONINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CELL VACUOLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS BREEDING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GENE MUTATION; GLYCOGEN ANALYSIS; GLYCOGEN STORAGE DISEASE; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PREEXCITATION; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; TRANSGENIC MOUSE;

ANIMALS; CARDIOTONIC AGENTS; ENZYME ACTIVATION; GLYCOGEN; HUMANS; MICE; MICE, TRANSGENIC; MULTIENZYME COMPLEXES; MUTATION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROTEIN-SERINE-THREONINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS; MUS MUSCULUS;

EID: 34447125085     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.06.067     Document Type: Article

References (20)

1. Kemp B.E., Mitchelhill K.I., Stapleton D., Michell B.J., Chen Z.P., and Witters L.A. Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem. Sci. 24 (1999) 22-25
2. Hardie D.G. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144 (2003) 5179-5183
3. Cheung P.C., Salt I.P., Davies S.P., Hardie D.G., and Carling D. Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem. J. 346 Pt 3 (2000) 659-669
4. Gollob M.H., Green M.S., Tang A.S., Gollob T., Karibe A., Ali Hassan A.S., Ahmad F., Lozado R., Shah G., Fananapazir L., Bachinski L.L., and Roberts R. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N. Engl. J. Med. 344 (2001) 1823-1831
5. Blair E., Redwood C., Ashrafian H., Oliveira M., Broxholme J., Kerr B., Salmon A., Ostman-Smith I., and Watkins H. Mutations in the gamma(2) subunit of AMP-activated protein kinase cause familial hypertrophic cardiomyopathy: evidence for the central role of energy compromise in disease pathogenesis. Hum. Mol. Genet. 10 (2001) 1215-1220
6. Arad M., Benson D.W., Perez-Atayde A.R., McKenna W.J., Sparks E.A., Kanter R.J., McGarry K., Seidman J.G., and Seidman C.E. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J. Clin. Invest. 109 (2002) 352-357
7. Arad M., Moskowitz I.P., Patel V.V., Ahmad F., Perez-Atayde A.R., Sawyer D.B., Walter M., Li G.H., Burgon P.G., Maguire C.T., Stapleton D., Schmitt J.P., Guo X.X., Pizard A., Kupershmidt S., Roden D.M., Berul C.I., Seidman C.E., and Seidman J.G. Transgenic mice overexpressing mutant PRKAG2 define the cause of Wolff-Parkinson-White syndrome in glycogen storage cardiomyopathy. Circulation 107 (2003) 2850-2856
8. Sidhu J.S., Rajawat Y.S., Rami T.G., Gollob M.H., Wang Z., Yuan R., Marian A.J., DeMayo F.J., Weilbacher D., Taffet G.E., Davies J.K., Carling D., Khoury D.S., and Roberts R. Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. Circulation 111 (2005) 21-29
9. Davies J.K., Wells D.J., Liu K., Whitrow H.R., Daniel T.D., Grignani R., Lygate C.A., Schneider J.E., Noel G., Watkins H., and Carling D. Characterization of the role of gamma2 R531G mutation in AMP-activated protein kinase in cardiac hypertrophy and Wolff-Parkinson-White syndrome. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H1942-H1951
10. Ahmad F., Arad M., Musi N., He H., Wolf C., Branco D., Perez-Atayde A.R., Stapleton D., Bali D., Xing Y., Tian R., Goodyear L.J., Berul C.I., Ingwall J.S., Seidman C.E., and Seidman J.G. Increased alpha2 subunit-associated AMPK activity and PRKAG2 cardiomyopathy. Circulation 112 (2005) 3140-3148
11. Gulick J., Subramaniam A., Neumann J., and Robbins J. Isolation and characterization of the mouse cardiac myosin heavy chain genes. J. Biol. Chem. 266 (1991) 9180-9185
12. Xing Y., Musi N., Fujii N., Zou L., Luptak I., Hirshman M.F., Goodyear L.J., and Tian R. Glucose metabolism and energy homeostasis in mouse hearts overexpressing dominant negative alpha2 subunit of AMP-activated protein kinase. J. Biol. Chem. 278 (2003) 28372-28377
13. Ramani R., Mathier M., Wang P., Gibson G., Togel S., Dawson J., Bauer A., Alber S., Watkins S.C., McTiernan C.F., and Feldman A.M. Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H1369-H1377
14. Zou L., Shen M., Arad M., He H., Lofgren B., Ingwall J.S., Seidman C.E., Seidman J.G., and Tian R. N488I mutation of the gamma2-subunit results in bidirectional changes in AMP-activated protein kinase activity. Circ Res. 97 (2005) 323-328
15. Hamilton S.R., Stapleton D., O'Donnell Jr. J.B., Kung J.T., Dalal S.R., Kemp B.E., and Witters L.A. An activating mutation in the gamma1 subunit of the AMP-activated protein kinase. FEBS Lett. 500 (2001) 163-168
16. Luptak I., Shen M., He H., Hirshman M.F., Musi N., Goodyear L.J., Yan J., Wakimoto H., Morita H., Arad M., Seidman C.E., Seidman J.G., Ingwall J.S., Balschi J.A., and Tian R. Aberrant activation of AMP-activated protein kinase remodels metabolic network in favor of cardiac glycogen storage. J. Clin. Invest. (2007)
17. Wojtaszewski J.F., Jorgensen S.B., Hellsten Y., Hardie D.G., and Richter E.A. Glycogen-dependent effects of 5-aminoimidazole-4-carboxamide (AICA)-riboside on AMP-activated protein kinase and glycogen synthase activities in rat skeletal muscle. Diabetes 51 (2002) 284-292
18. Polekhina G., Gupta A., Michell B.J., van Denderen B., Murthy S., Feil S.C., Jennings I.G., Campbell D.J., Witters L.A., Parker M.W., Kemp B.E., and Stapleton D. AMPK beta subunit targets metabolic stress sensing to glycogen. Curr. Biol. 13 (2003) 867-871
19. Russell III R.R., Li J., Coven D.L., Pypaert M., Zechner C., Palmeri M., Giordano F.J., Mu J., Birnbaum M.J., and Young L.H. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J. Clin. Invest. 114 (2004) 495-503
20. Li J., Hu X., Selvakumar P., Russell III R.R., Cushman S.W., Holman G.D., and Young L.H. Role of the nitric oxide pathway in AMPK-mediated glucose uptake and GLUT4 translocation in heart muscle. Am. J. Physiol. Endocrinol. Metab. 287 (2004) E834-E841